Non-small Cell Lung Cancer Stage I
22
4
5
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 22 trials
100.0%
+13.5% vs benchmark
9%
2 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (22)
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Adjuvant Chemotherapy for High-Risk Pathologic Stage I Non-Squamous NSCLC
Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer
SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS
SCION: SABR and Checkpoint Inhibition of NSCLC
Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer
Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer
Segmentectomy vs Lobectomy
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Method in Identification of Intersegmental Plane(IMPLANE-0529)
Mediastinal Staging Accuracy of a Selective Lymphadenectomy Strategy in Early Stage NSCLC (ECTOP-1003)
The Canada Lymph Node Score Project: A Crossover Trial
Traditional Chinese Medicine Combined With Thermal and Cold Ablation for Early-stage Lung Cancer
Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer
LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC
Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer